Saltar al contenido
MilliporeSigma

Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer.

Gastroenterology (2022-02-18)
Xiuhui Shi, Jingxuan Yang, Mingyang Liu, Yuqing Zhang, Zhijun Zhou, Wenyi Luo, Kar-Ming Fung, Chao Xu, Michael S Bronze, Courtney W Houchen, Min Li
RESUMEN

Pancreatic cancer has the highest prevalence of cancer-associated cachexia among all cancers. ZIP4 promotes pancreatic cancer progression by regulating oncogenic miR-373, and perturbation of circular RNAs (circRNAs) is associated with cancer aggressiveness. This study aimed to identify circRNAs involved in ZIP4/miR-373-driven cancer growth and cachexia and decipher the underlying mechanism. Differentially expressed circRNAs and potential targets of microRNA were identified through in silico analysis. The RNA interactions were determined by means of biotinylated microRNA pulldown, RNA immunoprecipitation, and luciferase reporter assays. The function of circRNA in ZIP4-miR-373 signaling axis were examined in human pancreatic cancer cells, 3-dimensional spheroids and organoids, mouse models, and clinical specimens. Mouse skeletal muscles were analyzed by means of histology. We identified circANAPC7 as a sponge for miR-373, which inhibited tumor growth and muscle wasting in vitro and in vivo. Mechanistic studies showed that PHLPP2 is a downstream target of ZIP4/miR-373. CircANAPC7 functions through PHLPP2-mediated dephosphorylation of AKT, thus suppressing cancer cell proliferation by down-regulating cyclin D1 and inhibiting muscle wasting via decreasing the secretion of transforming growth factor-β through STAT5. We further demonstrated that PHLPP2 induced dephosphorylation of CREB, a zinc-dependent transcription factor activated by ZIP4, thereby forming a CREB-miR-373-PHLPP2 feed-forward loop to regulate tumor progression and cancer cachexia. This study identified circANAPC7 as a novel tumor suppressor, which functions through the CREB-miR-373-PHLPP2 axis, leading to AKT dephosphorylation, and cyclin D1 and transforming growth factor-β down-regulation to suppress tumor growth and muscle wasting in pancreatic cancer.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Roche
cOmplete Protease Inhibitor Cocktail, Tablets provided in EASYpacks
Sigma-Aldrich
Actinomycin D, from Streptomyces sp., ~98% (HPLC)
Roche
Taq DNA Polymerase, dNTPack, suitable for PCR, optimum pH ~9.0 (20 °C), dNTPs included
Sigma-Aldrich
Monoclonal Anti-AGO2 antibody produced in rat, ~1.5 mg/mL, clone 11A9, purified immunoglobulin